Abstract
Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 313-318 |
| Number of pages | 6 |
| Journal | Seminars in Thrombosis and Hemostasis |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- anticoagulation
- bleeding
- cancer
- chemotherapy
- survival
- venous thromboembolism
ASJC Scopus subject areas
- Hematology
- Cardiology and Cardiovascular Medicine
- Medicine(all)
Cite this
Adverse impact of venous thromboembolism on patients with cancer. / Arora, Mili; Wun, Theodore.
In: Seminars in Thrombosis and Hemostasis, Vol. 40, No. 3, 2014, p. 313-318.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adverse impact of venous thromboembolism on patients with cancer
AU - Arora, Mili
AU - Wun, Theodore
PY - 2014
Y1 - 2014
N2 - Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
AB - Venous thromboembolism (VTE) is a common complication of malignancy. This is related to the underlying cancer and thrombogenic effects of various therapies. Compared with VTE in patients without malignancies, cancer-associated thrombosis is associated with increased mortality, recurrence, and bleeding while on anticoagulants. These worse outcomes are due to a complex interplay between the underlying cancer, host response, antitumor therapies, and interactions between anticoagulants and cancer drugs. Primary prevention of VTE may decrease morbidity and possibly even improve cancer-related survival, but studies to date have not clearly identified a patient population that might be of most benefit nor consistently shown a survival benefit to anticoagulation.
KW - anticoagulation
KW - bleeding
KW - cancer
KW - chemotherapy
KW - survival
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84897399233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897399233&partnerID=8YFLogxK
U2 - 10.1055/s-0034-1370769
DO - 10.1055/s-0034-1370769
M3 - Article
C2 - 24599435
AN - SCOPUS:84897399233
VL - 40
SP - 313
EP - 318
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
SN - 0094-6176
IS - 3
ER -